Skip to main content
Top
Published in: Diabetologia 6/2005

01-06-2005 | Article

Hyperglycaemia increases dipeptidyl peptidase IV activity in diabetes mellitus

Authors: E. Mannucci, L. Pala, S. Ciani, G. Bardini, A. Pezzatini, I. Sposato, F. Cremasco, A. Ognibene, C. M. Rotella

Published in: Diabetologia | Issue 6/2005

Login to get access

Abstract

Aims/hypotheses

Chronic hyperglycaemia increases dipeptidyl peptidase IV (DPP-IV) activity in endothelial cells in vitro. The present study was designed to assess the effect of high glucose on circulating DPP-IV activity in patients with type 1 and type 2 diabetes.

Methods

Plasma DPP-IV activity was measured in 29 patients with type 1 diabetes and 29 age-, sex- and BMI-matched control subjects. We also assessed DPP-IV activity in 31 type 2 diabetic patients with HbA1c >8.5% and in plasma from matched groups of 31 newly diagnosed diabetic subjects with HbA1c <7.5%, 31 subjects with IGT and 62 subjects with NGT. In a further sample of 66 type 2 diabetic patients, a longitudinal study was also performed to evaluate variations in DPP-IV activity and HbA1c over 3 months.

Results

DPP-IV activity in type 1 diabetic patients was not significantly different from that in control subjects; however, a significant correlation between DPP-IV and HbA1c was observed in diabetic subjects (r=0.47; p<0.01). Type 2 diabetic patients with HbA1c >8.5% showed significantly (p<0.05) higher DPP-IV activity (mean±SD 27.7±7.1 U/l) than newly diagnosed diabetic patients and subjects with IGT (22.1±6.0 and 18.8±8.8 U/l, respectively). Variations in DPP-IV activity over 3 months in type 2 diabetic patients showed a significant positive correlation with variations in HbA1c (r=0.26; p<0.05).

Conclusions/interpretation

Chronic hyperglycaemia induces a significant increase in DPP-IV activity in type 1 and type 2 diabetes. This phenomenon could contribute to the reduction in circulating active glucagon-like peptide-1 and to the consequent postprandial hyperglycaemia in type 2 diabetic patients with poor metabolic control.
Literature
1.
go back to reference Kreymann B, Williams G, Ghatei MA, Bloom SR (1987) Glucagon-like peptide-1 7–36: a physiological incretin in man. Lancet 2:1300–1304CrossRefPubMed Kreymann B, Williams G, Ghatei MA, Bloom SR (1987) Glucagon-like peptide-1 7–36: a physiological incretin in man. Lancet 2:1300–1304CrossRefPubMed
2.
go back to reference D’Alessio DA, Kahn SE, Leusner CR, Ensinck JW (1994) Glucagon-like peptide-1 enhances glucose tolerance both by stimulation of insulin release and by increasing insulin-independent glucose disposal. J Clin Invest 95:2263–2266 D’Alessio DA, Kahn SE, Leusner CR, Ensinck JW (1994) Glucagon-like peptide-1 enhances glucose tolerance both by stimulation of insulin release and by increasing insulin-independent glucose disposal. J Clin Invest 95:2263–2266
3.
go back to reference Gutzwiller JP, Goke B, Drewe J et al (1999) Glucagon-like peptide-1: a potent regulator of food intake in humans. Gut 44:81–86PubMed Gutzwiller JP, Goke B, Drewe J et al (1999) Glucagon-like peptide-1: a potent regulator of food intake in humans. Gut 44:81–86PubMed
4.
go back to reference Lugari R, Dell’Anna C, Ugolotti D et al (2000) Effect of nutrient ingestion on glucagon-like peptide-1 (7–36 amide) secretion in human type 1 and type 2 diabetes. Horm Metab Res 32:424–428PubMed Lugari R, Dell’Anna C, Ugolotti D et al (2000) Effect of nutrient ingestion on glucagon-like peptide-1 (7–36 amide) secretion in human type 1 and type 2 diabetes. Horm Metab Res 32:424–428PubMed
5.
go back to reference Vilsboll T, Krarup T, Deacon CF, Madsbad S, Holst JJ (2001) Reduced postprandial concentration of intact biologically active glucagon-like peptide-1 in type 2 diabetic patients. Diabetes 50:609–613PubMed Vilsboll T, Krarup T, Deacon CF, Madsbad S, Holst JJ (2001) Reduced postprandial concentration of intact biologically active glucagon-like peptide-1 in type 2 diabetic patients. Diabetes 50:609–613PubMed
6.
go back to reference Vaag AA, Holst JJ, Volund A, Beck-Nielsen HB (1996) Gut incretin hormones in identical twins discordant for non-insulin-dependent diabetes mellitus (NIDDM)—evidence for decreased glucagon-like peptide-1 secretion during oral glucose ingestion in NIDDM twins. Eur J Endocrinol 135:425–432PubMed Vaag AA, Holst JJ, Volund A, Beck-Nielsen HB (1996) Gut incretin hormones in identical twins discordant for non-insulin-dependent diabetes mellitus (NIDDM)—evidence for decreased glucagon-like peptide-1 secretion during oral glucose ingestion in NIDDM twins. Eur J Endocrinol 135:425–432PubMed
7.
go back to reference Mannucci E, Ognibene A, Cremasco F et al (2000) Glucagon-like peptide-1 (GLP-1) and leptin concentrations in obese patients with type 2 diabetes mellitus. Diabet Med 17:713–719CrossRefPubMed Mannucci E, Ognibene A, Cremasco F et al (2000) Glucagon-like peptide-1 (GLP-1) and leptin concentrations in obese patients with type 2 diabetes mellitus. Diabet Med 17:713–719CrossRefPubMed
8.
go back to reference Toft-Nielsen MB, Damholt MB, Madsbad S et al (2001) Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients. J Clin Endocrinol Metab 86:3717–3723CrossRefPubMed Toft-Nielsen MB, Damholt MB, Madsbad S et al (2001) Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients. J Clin Endocrinol Metab 86:3717–3723CrossRefPubMed
9.
go back to reference Schirra J, Sturm K, Leicht P, Arnold R, Goke B, Katschinski M (1998) Exendin (9–39) is an antagonist of glucagon-like peptide-1 (7–36) amide in humans. J Clin Invest 101:1421–1430PubMed Schirra J, Sturm K, Leicht P, Arnold R, Goke B, Katschinski M (1998) Exendin (9–39) is an antagonist of glucagon-like peptide-1 (7–36) amide in humans. J Clin Invest 101:1421–1430PubMed
10.
go back to reference Edwards CM, Todd JF, Mahmoudi M et al (1999) Glucagon-like peptide-1 has a physiological role in the control of post-prandial glucose in humans: studies with the antagonist exendin 9–39. Diabetes 48:86–93PubMed Edwards CM, Todd JF, Mahmoudi M et al (1999) Glucagon-like peptide-1 has a physiological role in the control of post-prandial glucose in humans: studies with the antagonist exendin 9–39. Diabetes 48:86–93PubMed
11.
go back to reference Mentlein R, Gallwitz B, Schmidt WE (1993) Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1-(7–36) amide, peptide histidine methionine, and is responsible for their degradation in human serum. Eur J Biochem 214:829–835CrossRefPubMed Mentlein R, Gallwitz B, Schmidt WE (1993) Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1-(7–36) amide, peptide histidine methionine, and is responsible for their degradation in human serum. Eur J Biochem 214:829–835CrossRefPubMed
12.
go back to reference Berghofer P, Peterson RG, Schneider K, Fehmann HC, Goke B (1997) Incretin hormone expression in the gut of diabetic mice and rats. Metabolism 46:261–267CrossRefPubMed Berghofer P, Peterson RG, Schneider K, Fehmann HC, Goke B (1997) Incretin hormone expression in the gut of diabetic mice and rats. Metabolism 46:261–267CrossRefPubMed
13.
go back to reference Vilsboll T, Agerso H, Krarup T, Holst JJ (2003) Similar elimination rates of glucagon-like peptide-1 in obese type 2 diabetic patients and healthy subjects. J Clin Endocrinol Metab 88:220–224CrossRefPubMed Vilsboll T, Agerso H, Krarup T, Holst JJ (2003) Similar elimination rates of glucagon-like peptide-1 in obese type 2 diabetic patients and healthy subjects. J Clin Endocrinol Metab 88:220–224CrossRefPubMed
14.
go back to reference Meneilly GS, Demuth HU, McIntosh CH, Pederson RA (2000) Effect of ageing and diabetes on glucose-dependent insulinotropic polypeptide and dipeptidyl peptidase IV responses to oral glucose. Diabet Med 17:346–350CrossRefPubMed Meneilly GS, Demuth HU, McIntosh CH, Pederson RA (2000) Effect of ageing and diabetes on glucose-dependent insulinotropic polypeptide and dipeptidyl peptidase IV responses to oral glucose. Diabet Med 17:346–350CrossRefPubMed
15.
go back to reference Pala L, Mannucci E, Pezzatini A et al (2003) Dipeptidyl peptidase-IV expression and activity in human glomerular endothelial cells. Biochem Biophys Res Commun 310:28–31CrossRefPubMed Pala L, Mannucci E, Pezzatini A et al (2003) Dipeptidyl peptidase-IV expression and activity in human glomerular endothelial cells. Biochem Biophys Res Commun 310:28–31CrossRefPubMed
16.
go back to reference Mannucci E, Ognibene A, Sposato I et al (2003) Fasting plasma glucose and glycated haemoglobin in the screening of diabetes and impaired glucose tolerance. Acta Diabetol 40:181–186CrossRefPubMed Mannucci E, Ognibene A, Sposato I et al (2003) Fasting plasma glucose and glycated haemoglobin in the screening of diabetes and impaired glucose tolerance. Acta Diabetol 40:181–186CrossRefPubMed
17.
go back to reference Durinx C, Neels H, Van der Auwera JC, Naelaerts K, Scharpe S, De Meester I (2001) Reference values for plasma dipeptidyl-peptidase IV activity and their association with other laboratory parameters. Clin Chem Lab Med 39:155–158CrossRefPubMed Durinx C, Neels H, Van der Auwera JC, Naelaerts K, Scharpe S, De Meester I (2001) Reference values for plasma dipeptidyl-peptidase IV activity and their association with other laboratory parameters. Clin Chem Lab Med 39:155–158CrossRefPubMed
18.
go back to reference Augustyns K, Bal G, Thonus G et al (1999) The unique properties of dipeptidyl-peptidase IV (DPP IV/CD 26) and the therapeutic potential of DPP-IV inhibitors. Curr Med Chem 6:311–327PubMed Augustyns K, Bal G, Thonus G et al (1999) The unique properties of dipeptidyl-peptidase IV (DPP IV/CD 26) and the therapeutic potential of DPP-IV inhibitors. Curr Med Chem 6:311–327PubMed
19.
go back to reference Mannucci E, Ognibene A, Cremasco F et al (2001) Effects of metformin on glucagon-like peptide-1 (GLP-1) and leptin levels in obese non-diabetic subjects. Diabetes Care 24:489–494PubMed Mannucci E, Ognibene A, Cremasco F et al (2001) Effects of metformin on glucagon-like peptide-1 (GLP-1) and leptin levels in obese non-diabetic subjects. Diabetes Care 24:489–494PubMed
20.
go back to reference Deacon CF, Nauck MA, Meier J, Hucking K, Holst JJ (2000) Degradation of endogenous and exogenous gastric inhibitory polypeptide in healthy and type 2 diabetic subjects as revealed using a new assay for the intact peptide. J Clin Endocrinol Metab 85:3575–3581CrossRefPubMed Deacon CF, Nauck MA, Meier J, Hucking K, Holst JJ (2000) Degradation of endogenous and exogenous gastric inhibitory polypeptide in healthy and type 2 diabetic subjects as revealed using a new assay for the intact peptide. J Clin Endocrinol Metab 85:3575–3581CrossRefPubMed
21.
go back to reference Rosenblum JF, Kozarich JW (2003) Prolyl peptidases: a serine protease subfamily with high potential for drug discovery. Curr Opin Chem Biol 7:496–504CrossRefPubMed Rosenblum JF, Kozarich JW (2003) Prolyl peptidases: a serine protease subfamily with high potential for drug discovery. Curr Opin Chem Biol 7:496–504CrossRefPubMed
22.
go back to reference Green BD, Mooney MH, Gault VA, Irwin N, Bailey CJ, Harriott P, Flatt PR, O’Harte FP (2004) Lys9 for Glu9 substitution in glucagon-like peptide-1(7–36)amide confers dipeptidylpeptidase-IV resistance with cellular and metabolic actions similar to those of established antagonists glucagon-like peptide-1(9–36)amide and exendin(9–39). Metabolism 53:252–259CrossRefPubMed Green BD, Mooney MH, Gault VA, Irwin N, Bailey CJ, Harriott P, Flatt PR, O’Harte FP (2004) Lys9 for Glu9 substitution in glucagon-like peptide-1(7–36)amide confers dipeptidylpeptidase-IV resistance with cellular and metabolic actions similar to those of established antagonists glucagon-like peptide-1(9–36)amide and exendin(9–39). Metabolism 53:252–259CrossRefPubMed
23.
go back to reference Wettergren A, Wojdemann M, Holst JJ (1998) The inhibitory effect of glucagon-like peptide-1 (7–36)amide on antral motility is antagonized by its N-terminally truncated primary metabolite GLP-1 (9–36)amide. Peptides 19:877–892CrossRefPubMed Wettergren A, Wojdemann M, Holst JJ (1998) The inhibitory effect of glucagon-like peptide-1 (7–36)amide on antral motility is antagonized by its N-terminally truncated primary metabolite GLP-1 (9–36)amide. Peptides 19:877–892CrossRefPubMed
Metadata
Title
Hyperglycaemia increases dipeptidyl peptidase IV activity in diabetes mellitus
Authors
E. Mannucci
L. Pala
S. Ciani
G. Bardini
A. Pezzatini
I. Sposato
F. Cremasco
A. Ognibene
C. M. Rotella
Publication date
01-06-2005
Publisher
Springer-Verlag
Published in
Diabetologia / Issue 6/2005
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-005-1749-8

Other articles of this Issue 6/2005

Diabetologia 6/2005 Go to the issue